Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease.

Pogoda, Christian; Brand, Stefan-Martin; Duning, Thomas; Schmidt-Pogoda, Antje; Sindermann, Jürgen; Lenders, Malte; Brand, Eva

Pogoda, Christian; Brand, Stefan-Martin; Duning, Thomas; Schmidt-Pogoda, Antje; Sindermann, Jürgen; Lenders, Malte; Brand, Eva.

Afiliación

Pogoda C; Department of Cardiology I-Coronary and Peripheral Vascular Disease, Heart Failure, and Interdisciplinary Fabry Center (IFAZ), University Hospital Münster, Münster, Germany.
Brand SM; Institute of Sports Medicine, Molecular Genetics of Cardiovascular Disease, and Interdisciplinary Fabry Center (IFAZ), University Hospital Münster, Münster, Germany.
Duning T; Department of Neurology, and Interdisciplinary Fabry Center (IFAZ), University Hospital Münster, Münster, Germany.
Schmidt-Pogoda A; Department of Neurology, Klinikum Bremen-Ost, Bremen, Germany.
Sindermann J; Department of Neurology, and Interdisciplinary Fabry Center (IFAZ), University Hospital Münster, Münster, Germany.
Lenders M; Interdisciplinary Heart Failure Section, University Hospital Münster, Münster, Germany.
Brand E; Department of Internal Medicine D, and Interdisciplinary Fabry Center (IFAZ), University Hospital Münster, Münster, Germany.

Front Cardiovasc Med ; 10: 1223635, 2023.

Article en En | MEDLINE | ID: mdl-38028489

Palabras clave

Fabry disease; cardiomyopathy; enzyme replacement therapy; left atrial strain; migalastat; speckle tracking

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Cardiovasc Med Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google